focus -WSS

focus

author：entertainment 2025-09-30 23:20:29 - browse：582

RHONA WISE/AFP via Getty Images

WASHINGTON — Drugmakers are doing everything to tap the bottomless well of demand for new obesity drugs, and they might get some government help. The agency that regulates Obamacare insurance is considering a technical change that would require insurers to cover obesity drugs in a market of more than 20 million Americans.

Weight loss drugs are a blessing for patients, a boon for drugmakers, and a potentially huge expense for insurers and taxpayers. Insurers have been slow to cover the drugs, called GLP-1 agonists, and without insurance, it costs upward of $16,000 annually for a drug that must be taken indefinitely.

There is a lot of demand for the drugs, but there are barriers to coverage. Medicare by law is prohibited from paying for obesity drugs. State Medicaid programs don’t have to cover them, so most don’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Food makers to regulators: Ultra

focus

WSS

Testing for cancer recurrence creates a new limbo for patients

Cassava reveals details — and problems — with Alzheimer's study

Physician subsidies by hospitals soar in wake of No Surprises Act

New weight loss drugs vying to be the next Wegovy or Mounjaro

How housing is health care on Long Island

FDA panel endorses Alnylam’s heart drug — after picking it apart

knowledge

focus

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

Will the IRA bring competition to the biologics market?

The cancer drug shortage isn’t new — and neither are the solutions

PEPFAR is under serious threat — and so is global health

Peter Hotez and the public health issue of online harassment

Hospitals consider fixing cancer drug shortages on their own

Apple is now the first public company to be valued at $3 trillion

PEPFAR is under serious threat — and so is global health

Medicare details structure of new drug price negotiation program

Testing for cancer recurrence creates a new limbo for patients

hotspot

Readout Newsletter: XBI biotech index, Akero Therapeutics

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

The FDA weighs the risks of candy

Food makers to regulators: Ultra

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Why Sanofi got shellacked over its spinoff

hotspot

focus

focus

entertainment